Project: Pre-clinical and clinical validation of a next-generation gabapentinoid for Neuropathic Pain

Acronym Drug for Neuropathic Pain (Reference Number: 113249)
Duration 06/01/2020 - 07/01/2022
Project Topic Validation of analgesic candidate NVA1309 to deliver: 1) GLP/Toxicology to estimate dose range for Phase I, guided by animal toxicity and 2) Completion of Ph I studies in healthy volunteers to generate pharmacokinetic/safety profiling and dose range for Ph IIa (Clinical Proof of Concept,C-PoC). This project exceeded threshold TWICE (ranked 70th and 78th in 2018 calls), but not funded due to Swiss budgetary restrictions. This is a re-submission addressing comments raised by reviewers.
Network Eurostars 2
Call Eurostars Cut–off 11

Project partner

Number Name Role Country
1 Novassay SA Coordinator Switzerland
2 3A(UK) Limited Partner United Kingdom
3 Richmond Pharmacology Limited Partner United Kingdom